Leukaemic subclones in chronic myelogenous leukaemia. Differences in drug sensitivity and in differentiation capacity.
D000368:Aged; D000856:Anorexia Nervosa / Q000209:etiology; D001772:Blood Cell Count; D001853:Bone Marrow / Q000032:analysis / Q000187:drug effects* / Q000378:metabolism; D001854:Bone Marrow Cells; D002066:Busulfan / Q000378:metabolism; D002454:Cell Differentiation; D002869:Chromosome Aberrations / Q000097:blood* / Q000187:drug effects; D025063:Chromosome Disorders; D002999:Clone Cells / Q000187:drug effects* / Q000378:metabolism; D003561:Cytarabine / Q000627:therapeutic use*; D005221:Fatigue / Q000209:etiology; D006801:Humans; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000097:blood / Q000150:complications / Q000473:pathology* / Q000532:radiotherapy; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D013160:Splenic Neoplasms / Q000532:radiotherapy; D013866:Thioguanine / Q000627:therapeutic use*
D003561:Cytarabine; D013866:Thioguanine; D002066:Busulfan